Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
Saved in:
| Title: | Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study. |
|---|---|
| Authors: | Singer, Barry A.1 (AUTHOR), Wray, Sibyl2 (AUTHOR), Gudesblatt, Mark3 (AUTHOR), Bumstead, Barbara3 (AUTHOR), Ziemssen, Tjalf4 (AUTHOR), Bonnell, Ashley2 (AUTHOR), Scaramozza, Matthew5 (AUTHOR), Levin, Seth5 (AUTHOR), Shanmugasundaram, Mathura5 (AUTHOR), Chen, Hailu5 (AUTHOR), Mendoza, Jason P.5 (AUTHOR), Lewin, James B.5 (AUTHOR), Shankar, Sai L.5 (AUTHOR) Sai.Shankar@Biogen.com |
| Source: | Neurology & Therapy. Aug2024, Vol. 13 Issue 4, p1273-1285. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 21938253 |
|---|---|
| DOI: | 10.1007/s40120-024-00637-2 |
